Development of a clinical trial protocol
As a result of the interaction of the above work packages, there will be new diagnostic markers and preclinically tested therapy options available. To pursue the translation of these results into clinical settings, special focus will be given to the development of protocols for innovative diagnostic and/or therapeutic clinical trials. This will be fostered by the activities and interaction of the clinical partners and neuropathologists of SYS-GLIO in the context of early clinical trials at the participating sites and later on within well-established clinical networks. Amongst others, we envisage clinical trials to prevent malignant progression, to induce differentiation or to specifically exploit the metabolic Achilles heels that distinguish glioma cells from untransformed brain parenchymal cells.